License to produce Lutetium-177 for clinical trials
ANSTO is proud to announce that a license has been issued by the Therapeutic Goods Administration to produce Lutetium-177 (Lu-177) for use in clinical trials.
Showing 301 - 320 of 485 results
ANSTO is proud to announce that a license has been issued by the Therapeutic Goods Administration to produce Lutetium-177 (Lu-177) for use in clinical trials.
Interested in a scholarship or graduate position at ANSTO? Review the opportunities at a glance.
Voucher scheme accelerating medical research
Blue Carbon Horizons Team showed coastal wetlands capture more carbon as sea levels rise
Proposals to Australian Centre for Neutron Scattering and National Deuteration Facility closed
Cyclotek and ANSTO have announced the launch of a Joint Venture (JV), to establish Australia’s first GMP (Good Manufacturing Practice) theranostics facility starting in Melbourne, Australia.
Science and medical experts meet in Adelaide to discuss great potential of particle therapy in Australia
Study helps make carbon dating a more accurate chronological tool.
Creating a global energy system that is both environmentally and economically sustainable is unquestionably one of the largest challenges facing the scientific and engineering communities.
Principal Technical Consultant Michael Druce shares some personal insights on the design and construction of ANSTO's nuclear medicine facility.